Vivos Therapeutics Company Insiders
VVOS Stock | USD 3.47 0.08 2.36% |
Vivos Therapeutics employs about 114 people. The company is managed by 10 executives with a total tenure of roughly 266 years, averaging almost 26.0 years of service per executive, having 11.4 employees per reported executive. Breaking down Vivos Therapeutics' management performance can provide insight into the firm performance.
Vivos |
Vivos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6087) % which means that it has lost $0.6087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2598) %, meaning that it created substantial loss on money invested by shareholders. Vivos Therapeutics' management efficiency ratios could be used to measure how well Vivos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Vivos Therapeutics Workforce Comparison
Vivos Therapeutics is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 511. Vivos Therapeutics totals roughly 114 in number of employees claiming about 22% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.69) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.69. Vivos Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vivos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vivos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vivos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bradford Amman over three weeks ago Acquisition by Bradford Amman of 100000 shares of Vivos Therapeutics at 7.5 subject to Rule 16b-3 | ||
Bradford Amman over three months ago Acquisition by Bradford Amman of 149533 shares of Vivos Therapeutics at 2.64 subject to Rule 16b-3 | ||
Huntsman Ronald Kirk over three months ago Acquisition by Huntsman Ronald Kirk of 5000 shares of Vivos Therapeutics at 4.31 subject to Rule 16b-3 | ||
Sokolow Leonard J over three months ago Disposition of 16667 shares by Sokolow Leonard J of Vivos Therapeutics at 7.5 subject to Rule 16b-3 | ||
Lindsay Mark F. over six months ago Acquisition by Lindsay Mark F. of 4000 shares of Vivos Therapeutics at 2.38 subject to Rule 16b-3 | ||
Huntsman Ronald Kirk over six months ago Acquisition by Huntsman Ronald Kirk of 500 shares of Vivos TherapeuticsInc at 8.5 subject to Rule 16b-3 | ||
Huntsman Ronald Kirk over a year ago Vivos TherapeuticsInc exotic insider transaction detected |
Vivos Therapeutics Notable Stakeholders
A Vivos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vivos Therapeutics often face trade-offs trying to please all of them. Vivos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vivos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Susan McCullough | CoFounder Operations | Profile | |
RaeAnn Byrnes | CoFounder Services | Profile | |
Kirk Huntsman | Chairman CoFounder | Profile | |
Julie Gannon | Chief Relations | Profile | |
Nicholas DeGennaro | Senior Division | Profile | |
John Ballard | Senior Technology | Profile | |
Ruth Hembree | Senior Services | Profile | |
Todd Huntsman | CoFounder Technology | Profile | |
Stephanie Huebner | Senior Integration | Profile | |
Bradford Amman | Treasurer CFO | Profile |
About Vivos Therapeutics Management Performance
The success or failure of an entity such as Vivos Therapeutics often depends on how effective the management is. Vivos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vivos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vivos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea , and snoring in adults. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 165 people.
Please note, the imprecision that can be found in Vivos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vivos Therapeutics. Check Vivos Therapeutics' Beneish M Score to see the likelihood of Vivos Therapeutics' management manipulating its earnings.
Vivos Therapeutics Workforce Analysis
Traditionally, organizations such as Vivos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vivos Therapeutics within its industry.Vivos Therapeutics Manpower Efficiency
Return on Vivos Therapeutics Manpower
Revenue Per Employee | 121.1K | |
Revenue Per Executive | 1.4M | |
Net Loss Per Employee | 119.1K | |
Net Loss Per Executive | 1.4M |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.